Zdrowie i gospodarka · 15/11/2024
FDA Publishes Draft Guidance on Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics
The FDA is releasing a draft guidance to help industry prepare for the nonclinical safety evaluation of oligonucleotide-based therapeutics, which will inform clinical development and marketing of these products.